ABC | Volume 113, Nº1, July 2019

Statement Statement on Antiplatelet Agents and Anticoagulants in Cardiology – 2019 Arq Bras Cardiol. 2019; 113(1):111-134 a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071-104. Erratum in: Circulation. 2014;130(23):e270-1. 71. Bungard TJ, Ackman ML, Ho G, Tsuyuki RT. Adequacy of anticoagulation in patients with atrial fibrillation coming to a hospital. Pharmacotherapy. 2000;20(9):1060-5. 72. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med. 1999;131(12):927-34. 73. Szekely P. Systemic embolismand anticoagulant prophylaxis in rheumatic heart disease. Br Med J. 1964;1(5392):1209-12. 74. Stewart RA. Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation. Curr Opin Cardiol. 2011;26(4):294-9. 75. Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol. 1998;82(12):1545-7. 76. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123(2):131-6. 77. Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, et al; ARISTOTLE Committees and Investigators. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63(11):1082-7. 78. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, et al; X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346-55. 79. Goette A, Merino JL, Ezekowitz M, Zamoryakhin D, Melino M, Jin J, et al; ENSURE-AF investigators.Edoxabanversusenoxaparin-warfarin inpatients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3B trial. Lancet. 2016;388(10055):1995-2003. 80. Kinch JW, Davidoff R. Prevention of embolic events after cardioversion of atrial fibrillation. Current and evolving strategies. Arch Intern Med. 1995;155(13):1353-60. 81. Gentile F, Elhendy A, Khandheria BK, Seward JB, Lohse CM, ShenWK, et al. Safety of electrical cardioversion in patients with atrial fibrillation. Mayo Clin Proc. 2002;77(9):897-904. 82. Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J AmColl Cardiol. 1992;19(4):851-5. 83. Khan IA. Atrial stunning: basic and clinical considerations. Int J Cardiol. 2003;92(2-3):113-28. 84. Manning WJ, Silverman DI, Katz SE, Riley MF, Come PC, Doherty RM, et al. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J AmColl Cardiol. 1994;23(7):1535-40. 85. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. 86. Pritchett EL. Management of atrial fibrillation. N Engl J Med. 1992;326(19):1264-71. 87. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al;RE-LYSteeringCommitteeand Investigators.Dabigatranversuswarfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. Erratum in: N Engl J Med. 2010;363(19):1877. 88. Botkin SB, Dhanekula LS, Olshansky B. Outpatient cardioversion of atrial arrhythmias: efficacy, safety, and costs. AmHeart J. 2003;145(2):233-8. 89. Singer DE, Hughes RA, Gress DR, SheehanMA, Oertel LB, Maraventano SW, et al; Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323(22):1505-11. 90. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84(2):527-39. 91. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343(8899):687-91. 92. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo- controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1(8631):175-9. 93. EzekowitzMD,BridgersSL,JamesKE,CarlinerNH,CollingCL,GornickCC, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention inNonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992;327(20):1406-12. Erratum in: N Engl J Med 1993;328(2):148. 94. ConnollySJ,LaupacisA,GentM,RobertsRS,Cairns JA, JoynerC.Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18(2):349-55. 95. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154(13):1449-57. Erratum in: Arch Intern Med. 1994;154(19):2254. 96. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-67. 97. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288(19):2441-8. 98. Cooper NJ, Sutton AJ, Lu G, Khunti K. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med. 2006;166(12):1269-75. 99. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, et al; ROCKET AF Steering Committee & Investigators. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013;61(19):1998-2006. 100. Pallisgaard JL, Lindhardt TB, HansenML, Schjerning AM, Olesen JB, Staerk L, et al. Cardioversion and risk of adverse events with dabigatran versus warfarin: a nationwide cohort study. PLoSOne. 2015;10(10):e0141377. 101. Nuotio I, Hartikainen JE, Gronberg T, Biancari F, Airaksinen KE. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA. 2014;312(6):647-9. 102. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, et al; Assessment of Cardioversion Using Transesophageal Echocardiography Investigators.Useoftransesophagealechocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344(19):1411-20. 103. Bartel T, Erbel R; Acute Trial Investigators. Transoesophageal echocardiography for immediate and safe cardioversion in patients with atrial fibrillation. Eur Heart J. 2001;22(22):2041-4. 104. Gallagher MM, Hennessy BJ, Edvardsson N, Hart CM, ShannonMS, Obel OA, et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol. 2002;40(5):926-33. 105. Weigner MJ, Caulfield TA, Danias PG, SilvermanDI, ManningWJ. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997;126(8):615-20. 106. Kim M, Trohman R, Eagle K. Low molecular weight heparin in atrial fibrillation management: facts, fiction, future. Card Electrophysiol Rev. 2003;7(4):397-400. 107. Serrano Junior CV, Fenelon G, Soeiro AM, Nicolau JC, Piegas LS, Montenegro ST, et al. Sociedade Brasileira de Cardiologia. Diretrizes 130